Inovio Pharma (NQ: INO )
10.10 USD +0.44 (+4.55%) Official Closing Price Updated: 5:14 PM EST, Jan 19, 2021 Add to My Watchlist
Press releases about Inovio Pharma
Biotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma
July 11, 2016
Inovio Pharmaceuticals and GeneOne Life Science Receive Approval for First-in-Man Zika Vaccine Clinical Trial
June 20, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science, Inc. (KSE:011000) today announced that they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA...
Inovio Pharmaceuticals Zika Vaccine Produces Robust Immune Responses in Non-Human Primates
May 16, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported that the Company will present a corporate overview at the UBS Global Healthcare Conference on Wednesday, May 25th at 8:30AM EDT.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended March 31, 2016.
Inovio Pharmaceuticals Showcases its Broad Pipeline of DNA-based Immunotherapies, Vaccines and dMAbs at the American Society of Gene & Cell Therapy
May 04, 2016
Worldwide Scientific Forum Selects Inovio’s Ebola Vaccine Challenge Results for its Presidential Symposium
Inovio will integrate needle-free injection with needle-free electroporation delivery in next-generation device for large-population vaccine administration
Inovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial
April 27, 2016
DNA-based immunotherapy will be tested for safety and immune responses in quest to eliminate HCV infection
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2016 first quarter financial results on Monday, May 9, 2016 at 8:30 a.m....
Human immunogenicity data combined with efficacy in multiple animal species warrants further human study
Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress
March 30, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its immunotherapy to treat cervical dysplasia (VGX-3100) was recognized as "Best Therapeutic Vaccine" by the World Vaccine Congress held...
Inovio Updates INO-3112 HPV Immunotherapy Development Plan
March 29, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical strategy update to take its INO-3112 HPV immunotherapy into human studies in combination with selected immunotherapy molecules from...
Inovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study
March 21, 2016
Ability of unique dMAb and DNA vaccine combination to induce rapid short-term and long-term protection has broad implications for infectious disease prevention and control
Covered Call Alerts For Marathon Oil Corporation, Amazon.com, Chesapeake Energy, ConocoPhillips and Inovio Pharmaceuticals Released By InvestorsObserver
March 16, 2016
Inovio Signs Collaborative Research Agreements With Wistar Institute for DNA-based Immunotherapies and Vaccines
March 16, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has signed collaborative research agreements (CRAs) with the Wistar Institute for preventive and therapeutic DNA-based immunotherapy...
Inovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation Vaccines
March 14, 2016
Non-invasive integrated injection and electroporation device to enhance mass immunization against flu, RSV, and pandemic/tropical infectious diseases using transformative immune-activating technology
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2015.
Inovio Pharmaceuticals Appoints DNA Immunotherapy Pioneer David B. Weiner, Ph.D., to its Board of Directors
March 11, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that David B. Weiner, Ph.D., recognized in scientific circles as the “father of DNA vaccines and immunotherapies,” has been appointed to...
Covered Call Alerts For Bank of America, Twitter, Inovio Pharmaceuticals, Marathon Oil Corporation and Amicus Therapeutics Released By InvestorsObserver
March 03, 2016
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2015 Financial Results on March 14, 2016
March 03, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2015 fourth quarter and year-end financial results on Monday, March 14, 2016...
Covered Call Alerts For Freeport-McMoRan, Inovio Pharmaceuticals, Chevron, NVIDIA and Groupon Released By InvestorsObserver
February 17, 2016
Inovio Pharmaceutical's DNA Vaccine for Zika Virus Induces Robust Immune Responses in Preclinical Study
February 16, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential...
Early Briefing on Biotechnology Stocks -- Achillion Pharma, CTI BioPharma, Inovio Pharma, and Keryx Biopharma
February 10, 2016
Tags Publishing & Media
Inovio Pharmaceuticals Inc. (NASDAQ: INO) Working on a Zika Vaccine
February 09, 2016
WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
February 03, 2016
Covered Call Alerts For Opko Health, Fitbit, Box, Inovio Pharmaceuticals and AbbVie Released By InvestorsObserver
February 02, 2016
Inovio Pharmaceuticals to Participate in Upcoming Investor Conferences
February 02, 2016
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that management will participate at three upcoming investor conferences in February: